Reviewer’s report

Title: Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: A case report.

Version: 0 Date: 22 Mar 2020

Reviewer: Carlo Alberto Artusi

Reviewer's report:

This is an interesting and well-presented case report adding further evidence on the possible development of PS in Alzheimer patients treated with AchEI. The novelty of the case is represented by the fact that PS seems to be selectively provoked by a specific AchEI (galantamine) after switching from donepezil. The discussion is well-documented.

Some minor edits need to be addressed:

* Abstract. When explaining the hypotheses, please avoid using the term dystonia since, in most cases, PS has uncertain pathogenesis, and dystonia is only one of the hypotheses, but no clues of dystonia (such as sensory trick, overflow, nor electromyographic signs of co-contraction) have been observed so far.
* Introduction. As for the comment above, please avoid starting defining PS as a form of dystonia because this is incorrect for what we know so far. I suggest for the definition of PS to cite the paper form Doherty et al. (2011). and Tinazzi et al. (2016). On the other hand, it is fine, a few lines below, to consider and report cases of PS considered as tardive dystonia.
* Page 3, lines 23-26. I suggest rephrasing as follows: "… Disruption of the cholinergic-dopaminergic balance could result in an asymmetric axial muscle tone activation, and this is the hypothesized pathogenic mechanism underlying the development of drug-induced PS."
* Case presentation. Please, give more details on how other parkinsonian signs and symptoms have changed after the removal of galantamine. Is freezing improved, for example?
* Discussion. Based on recent literature data associating PS with visual-spatial function impairment (Artusi et al., 2019; Vitale et al., 2016) and the remarkable involvement of these functions in the reported patient, I suggest extending the discussion of your case.
* Page 6, lines 16-17. Please, rephrase the following as follows: "The Naranjo score of 5 indicates that galantamine was the probable cause of PS in our case."

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**

If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**

Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organisation that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

No competing interest

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal